Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, as well as data from the Global aHUS Registry, at the 56th Annual Meeting of the American Society of Hematology (ASH). Soliris is the first and only approved treatment for PNH and aHUS. Abstracts summarizing these presentations are published on the ASH website and can be accessed using the links below. The ASH annual meeting will be held December 6-9, 2014, in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
